Introduction: Patients with brain metastases (BMs) arising from EGFR-mutated and anaplastic lymphoma kinase gene (ALK)-rearranged NSCLC have a favorable prognosis compared with patients with non-oncogene-addicted NSCLC, emphasizing the importance of minimizing toxicities such as the cognitive sequelae of whole brain radiation therapy (WBRT). Although radiosurgery without WBRT is the preferred strategy for one to three BMs, this paradigm remains controversial for patients with multiple BMs.
Introduction
The natural history and prognosis of patients with brain metastases (BMs) from EGFR-mutated and anaplastic lymphoma kinase gene (ALK)-rearranged NSCLC are distinct from those of patients with non-oncogene-addicted NSCLC, with median survival (MS) after the development of BMs measured in years. 1, 2 Consequently, the optimal management of BMs in these patients is a matter of considerable *Corresponding author.
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debate. Effective central nervous system (CNS) control remains a priority, yet the importance of minimizing toxicities such as the cognitive sequelae of whole brain radiation therapy (WBRT) [3] [4] [5] is magnified in patients with long-term survival. Radiosurgery is the preferred treatment strategy for one to three BMs, but it remains controversial for four or more BMs. 6 Given their extended prognosis and the emergence of targeted therapies with enhanced CNS penetration, 7, 8 patients with EGRF-mutated and ALK-rearranged NSCLC may be uniquely suited to benefit from a strategy of radiosurgery without WBRT for multiple BMs. We therefore reviewed our experience utilizing radiosurgery for patients with EGFR-mutated and ALK-rearranged NSCLC who received treatment to four or more BMs in a single session, and we included patients treated with multiple courses of radiosurgery.
Material and Methods
We reviewed the records of patients with EGRFmutated and ALK-rearranged NSCLC between 2008 and 2017. We included only patients who received treatment to four or more BMs with radiosurgery in a single session without limits for number of radiosurgery courses or total BMs treated. Freedom from CNS progression (FFCNSP) was defined as the interval without CNS progression after each radiosurgery course. Patients who underwent WBRT before radiosurgery were excluded from analysis for freedom from whole brain radiation therapy (FFWBRT). In most cases (72%), we were able to retrieve the original treatment plan, and hippocampus and whole brain volumes were retrospectively contoured. Representative WBRT cases prescribed to 30 Gy in 10 fractions were used for hippocampal-sparing whole brain intensity-modulated radiation therapy (HS-WB-IMRT) (n ¼ 3) and non-hippocampal-sparing WBRT (non-HS-WBRT) (n ¼ 3) dosimetry. GraphPad Prism (version 5.03, GraphPad Software, La Jolla, CA) was used for creation of the figures.
Results
We identified 35 patients for analysis. Nineteen (54%) had ALK-rearranged tumors and 16 (46%) had EGRFmutated tumors. Eighteen of 35 patients (51%) had BMs at first presentation of metastatic disease. Thirty patients (86%) received treatment to four to 10 BMs in a single session, and five patients (14%) received treatment to more than 10 BMs in a single session. The median number of BM treated in a single radiosurgery session was 6. Thirteen patients (37%) underwent a single radiosurgery session, whereas the remaining 22 patients (63%) required additional radiosurgery courses (range 2-6), with a median of 4.5 additional lesions treated over subsequent courses (range 1-39). Sixteen patients (46%) received treatment to more than 10 BMs in total throughout all radiosurgery courses (range 4-47). The median number of BM treated in total throughout all radiosurgery courses was 10. Twenty patients (57%) received CNS-active tyrosine kinase inhibitors (TKIs) at some point during their treatment course after the diagnosis of BMs (Table 1) .
Median follow-up after the diagnosis of BM was 4.1 years, and MS was 3.0 years (4.2 years for ALK-rearranged NSCLC and 2.4 years for EGRF-mutated NSCLC) (Fig. 1A) . MS from the diagnosis of BM was comparable with respect to number of radiosurgery courses (one versus two versus three or more [p ¼ 0.761]) (Fig. 1B) , total number Osimertinib, ceritinib, alectinib, brigatinib, and lorlatinib (additional patients received erlotinib, afatinib, crizotinib, and rociletinib, which were not considered CNS-active agents). ALK, anaplastic lymphoma kinase gene; SRS, stereotactic radiosurgery; CNS, central nervous system; WBRT, whole brain radiation therapy.
of metastases treated over all radiosurgery courses (four to 10 versus 11-20 versus >20 [p ¼ 0.621]) (Fig. 1C) , and maximum number of metastases treated in a single radiosurgery session (four to 10 versus >10 [p ¼ 0.524]) (Fig. 1D) . FFCNSP1 (the interval without CNS progression after radiosurgery course one) was 7.8 months, FFCNSP2 (the interval without CNS progression after radiosurgery course two) was 6.8 months, and FFCNSP3 (the interval without CNS progression after radiosurgery course three) was 3.2 months. A median of five, five, and eight BMs were treated during the first, second, and third radiosurgery courses, respectively ( Fig. 2A) . The 5-year FFWBRT was 97% (Fig. 2B) . Neurologic death was classified as follows: likely, four cases; unlikely or alive, 30 cases; and unknown, one case (excluded from analysis of neurologic mortality). The 5-year freedom from neurologic mortality rate was 84% (Fig. 2C) . Receipt of CNS-active TKIs after the diagnosis of BM was associated with improved survival (p < 0.001) (Fig. 2D) . Radiosurgery was reasonably well tolerated overall. The rates of radiation necrosis (RN) by lesion and by patient were seven of 516 (1.4%) and four of 35 (11.4%), respectively. RN occurred at a median of 9.9 months (4.6-18.7 months) after radiosurgery and was managed with corticosteroids (n ¼ 3) or bevacizumab (n ¼ 1). The cases of RN were reviewed in detail. Two of the four patients underwent multiple radiosurgery courses (2 and 3), but for all four patients in whom RN developed, it was related to the first radiosurgery course. The number of BMs treated during the course leading to RN was variable: four, four, nine, and 10. RN of four lesions developed in the patient who received treatment to 10 BMs, whereas RN of only one lesion developed in the other three patients. The median volume of treated BMs in which RN developed was 0.98 cm 3 (range 0.16-11.59 cm 3 ). The large BM (11.59 cm 3 ) was treated with 24 Gy in three fractions, whereas the other BMs in which RN developed all received 18 to 20 Gy in a single fraction. In addition to the four patients with development of RN, one patient underwent an endoscopic third ventriculostomy (0.7 months after radiosurgery) for obstructive hydrocephalus from acute tumor swelling, and this patient remains alive without additional neurologic complications over 18 months from radiosurgery.
Finally, we compared normal tissue dosimetry. The mean hippocampal doses were 0.2 Gy, 1.2 Gy, and 1.2 Gy for the patients with one to three, four to 10, and more
A B C D Figure 1. Kaplan-Meier survival curves for OS from diagnosis of brain metastases (A), and stratified by number of stereotactic radiosurgery (SRS) courses (B), total number of metastases treated over all SRS courses (C), and maximum number of metastases treated in a single SRS course (D).
May 2018 Radiosurgery for Multiple Brain Metastasesthan 10 treated metastases, respectively. This compares with a mean hippocampal dose of 10.6 Gy for HS-WB-IMRT and 30.3 Gy for non-HS-WBRT (Fig. 3A) The mean whole brain dose was less than 1 Gy in all radiosurgery groups (0.3 Gy with one to three metastases, 0.6 Gy with four to 10 metastases, and 0.8 Gy with more than 10 metastases:), 31.9 Gy for HS-WB-IMRT, and 30.9 Gy for non-HS-WBRT (Fig. 3B). A B . CNS-active systemic agents included osimertinib, ceritinib, alectinib, brigatinib, and lorlatinib (additional patients received erlotinib, afatinib, crizotinib, and rociletinib, which were not considered CNS-active agents).
Discussion
EGFR mutations and ALK rearrangements occur in approximately 10% and 3% to 7% of all NSCLC tumors, respectively. [9] [10] [11] In patients with EGRF-mutated and ALK-rearranged NSCLC, BMs frequently develop during the disease course 7, 12 and optimal CNS management remains controversial. There are limited prospective data to support radiosurgery alone for four or more metastases, but the alternative, WBRT with or without radiosurgery, is associated with consistent measurable cognitive toxicities. [3] [4] [5] We did include six patients who received WBRT before radiosurgery in this analysis, as our primary objective was to assess outcomes for patients who received treatment with radiosurgery to four or more BMs, but our data set is largely composed of patients managed with radiosurgery alone. The best available data for radiosurgery alone for multiple BMs come from Yamamoto et al. and show in a large multiinstitutional prospective cohort of mixed histologic types (76% lung) that survival, complication rates, and changes in the Mini-Mental State Examination score are similar in patients who receive treatment with radiosurgery alone to five to 10 metastases compared with two to four metastases. 13, 14 This study builds on the data of Yamamoto et al. 13, 14 specifically for patients with EGFR-mutated and ALK-rearranged NSCLC, a cohort with prolonged MS from the time of BM development and emerging systemic therapy options with enhanced CNS activity. 1, 2, 7, 8, 15, 16 We have focused on patients with multiple BMs and observed that patients who received treatment to more than 10 metastases in a single radiosurgery session have comparable survival to that of patients who received treatment to four to 10 metastases. Further, Yamamoto et al. 13, 14 report on first radiosurgery course, but our analysis includes a survival analysis of repeated radiosurgery courses and we found no appreciable difference in MS comparing one radiosurgery course with multiple courses. Although patients undergoing multiple radiosurgery courses had comparable MS to that of patients undergoing only one radiosurgery session, it is important to note that in this cohort of patients who received treatment to multiple BMs, salvage radiosurgery courses were ultimately required in most patients (63%).
Despite multiple courses of radiosurgery and targeting of multiple lesions, radiosurgery was reasonably well tolerated overall, with development of symptomatic RN in only seven of the total of 516 treated BMs (1.4%), or in four of 35 patients (11.4%). The reported rates of RN in large cooperative group studies treating one to three lesions range from 4.5% to 11%, 4, 17 which is comparable with our findings in a cohort where many more lesions were treated with radiosurgery per patient. Moreover, the reported rate of symptomatic RN by lesion in a very large institutional series was 10%, 18 but the rate was only 1.4% in this cohort. Increasing lesion size is associated with increased risk for RN, 17 and although the large lesion that developed RN in our series was treated in three fractions 19 instead of a single fraction, lesion size was still likely related to the development of RN in this patient. However, no factors were clearly associated with the development of RN in the other cases in our series.
Overall, the data presented in this analysis support strategies of radiosurgery without WBRT even in patients with progression in the CNS after prior radiosurgery. Importantly, we reviewed cause of death in our cohort, and the rates of neurologic death were comparable to those seen in a large multi-institutional database in which half of patients received WBRT, 2 suggesting that the omission of WBRT for a high number of BMs was not associated with increased neurologic mortality. Receipt of CNS-active TKIs was associated with a significant improvement in MS, suggesting that the paradigm of radiosurgery alone for four or more BMs should be strongly considered in patients eligible to receive CNS-active systemic therapy.
Although our study presents encouraging results, it is important to note that our data are subject to several limitations. In particular, we cannot account for selection bias in this retrospective cohort. Further, we were unable to formally assess cognitive toxicity in this retrospective analysis. To address this issue, we assessed hippocampus and whole brain dosimetry as a surrogate and found very low mean doses to the hippocampus and whole brain even among patients who received treatment to more than 10 metastases in a single session.
Overall, this analysis suggests that radiosurgery alone is an effective strategy in the management of patients with EGFR-mutated and ALK-rearranged NSCLC with multiple BMs and that outcomes remain encouraging even for patients with very high numbers of BMs and for those patients who undergo multiple courses of radiosurgery.
